ELCC oral 2019: Entrectinib in NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Integrated Analysis of Patients Enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
Entrectinib is an oral, potent and selective ROS1/NTRK/ALK tyrosine kinase inhibitor that is CNS active. It is a more potent ROS1 inhibitor than crizotinib and was designed to cross the blood–brain barrier and remain within the CNS. This is a pooled analysis of three studies of entrectinib focusing on patients with NTRK-fusion-positive NSCLC.
Receive this presentation and more content via email